MindPharm Blog

A California Institute of Technology (Caltech)-led team of researchers and clinicians has published the first proof that a targeted nanoparticle?used as an experimental therapeutic and injected directly into a patient?s bloodstream?can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene.


Caltech-led Team Provides Proof in Humans of RNA Interference Using Targeted Nanoparticles - Caltech

These results, published in the March 21 advance online edition of the journal Nature, demonstrate the feasibility of using both nanoparticles and RNAi-based therapeutics in patients, and open the door for future "game-changing" therapeutics that attack cancer and other diseases at the genetic level, says Mark Davis, the Warren and Katharine Schlinger Professor of Chemical Engineering at Caltech, and the research team?s leader.